159660-85-2

Usage

Chemical Properties

light orange crystals or crystalline powder

InChI:InChI=1/C14H18N2O2/c1-18-14(17)12-10-16(8-7-13(12)15)9-11-5-3-2-4-6-11/h2-6,12,15H,7-10H2,1H3/p+1/b15-13+/t12-/m0/s1

Upstream product

• 57611-47-9 1-benzyl-4-oxo-piperidine-3-carboxylic acid methyl ester 
• 3939-01-3 methyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 

Downstream Products

• 135481-57-1 5,6,7,8-tetrahydro-6-(phenylmethyl)pyrido<3,4-d>pyrimidine-2,4(1H,3H)-dione 
• 160956-42-3 (Z)-(1-benzyl-2-oxotetrahydropyrimidin-4-ylidene)acetic acid methyl ester 
• 332097-95-7 (6-benzyl-2-chloro-4-oxo-5,6,7,8-tetrahydro-4H-pyrido[4,3-d]pyrimidin-3-yl)-acetic acid ethyl ester 
• 332097-94-6 ethyl 6-benzyl-3,4,5,6,7,8-hexahydro-2-methylthio-4-oxopyrido[4,3-d]pyrimidine-3-acetate 
• 892863-69-3 ethyl 4-amino-1-benzyl-3-piperidinecarboxylate 
• 109229-22-3 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one 
• 332097-92-4 ethyl 6-benzyl-1,2,3,4,5,6,7,8-octahydro-4-oxo-2-thioxopyrido[4,3-d]pyrimidine-3-acetate 
• 159660-87-4 6-benzyl-3-methyl-5,6,7,8-tetrahydro-1H-pyrido<4,3-d>pyrimidine-2,4-one 

Relevant academic research and scientific papers

PROTEIN KINASE REGULATORS

The present invention provides, in part, novel compounds and pharmaceutically acceptable salts capable of modulating the activity of kinases, including Akt, ERK and MEK. Such modulation affects biological functions, for example, by inhibiting cell proliferation and/or inducing apoptosis. Also provided are pharmaceutical compositions and medicaments, comprising the compounds or salts of the invention, alone or in combination with other therapeutic agents or palliative agents.

4-Aminopiperidine derivatives

The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or β-cell protection.

Pyridopyrimidinediones, processes for their preparation and their use as drugs

Pyridopyrimidinediones, processes for their preparation and their use as drugs A compound of the formula I: STR1 and/or physiologically acceptable salts of the compound of the formula I, and/or optionally stereoisomeric forms of the compound of the formul